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Hepatitis C virus (HCV) is a major cause of liver disease throughout the world. The NS5A and E2 proteins of 
HCV genotype 1 were reported to inhibit the double-stranded (ds) RNA-dependent protein kinase (PKR), which is 
involved in the cellular antiviral response induced by interferon (IFN). The response to IFN therapy is quite different 
between genotypes, with response rates among patients infected with types 2 and 3 that are two-three-fold higher 
than in patients infected with type 1. Interestingly, a significant percentage of HCV genotype 3-infected patients 
do not respond to treatment at all. The aim of this paper was to analyse the sequences of fragments of the E2 and 
NS5A regions from 33 outpatients infected with genotype 3a, including patients that have responded (SVR) or not 
responded (NR) to treatment. HCV RNA was extracted and amplified with specific primers for the NS5A and E2 
regions and the PCR products were then sequenced. The sequences obtained covered amino acids (aa) 636-708 in 
E2 and in NS5A [including the IFN sensitivity determining region (ISDR), PKR-binding domain and extended V3 
region)]. In the E2 and NS5A regions, we did observe aa changes among patients, but these changes were not statis-
tically significant between the SVR and NR groups. In conclusion, our results suggest that the ISDR domain is not 
predictive of treatment success in patients infected with HCV genotype 3a.
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Hepatitis C virus (HCV) is a member of the Flavi-
viridae family which usually causes chronic infection 
and can result in chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma. The only drug that effectively 
reduces viral load is interferon-α (IFN-α) (Chayama et 
al. 2000). Current therapy, a combination of pegylated 
IFN-α and ribavirin (RBV), achieves a response rate be-
tween 48-88% (Poynard et al. 2003). Individuals infect-
ed with HCV genotype 1a/b show response rates of 38-
52%, whereas 66-88% of those infected with genotypes 
2 and 3 achieve sustained virological response (SVR). 
It is likely that the sensitivity or resistance to antiviral 
therapy is governed by both the virus and the host itself 
(Goyal et al. 2007).
The ability of HCV to evade the antiviral effects of 
IFN-α has been previously reported. Both the HCV en-
velope E2 protein and the nonstructural NS5A protein 
of HCV-1a/b isolates have been shown to inhibit IFN-α 
induced double-stranded RNA-activated protein kinase 
(PKR) in vitro (Gale et al. 1998a, Taylor et al. 1999). Tay-
lor et al. (1999) reported that HCV E2 protein contains a 
12 amino acid (aa) domain that is highly homologous to 
the autophosphorylation site of PKR and initiation factor 
eIF2a, a target of PKR [the PKR-eIF2a phosphorylation 
homology domain (PePHD)]. They showed that E2 pro-
tein inhibited the kinase activity of PKR and blocked its 
inhibitory effect on protein synthesis and cell growth, 
suggesting that the interaction of E2 and PKR may be 
one of the mechanisms by which HCV circumvents the 
antiviral effects of IFN.
NS5A has also been studied as a possible mediator 
of IFN-α resistance (Hofmann et al. 2005). A binding 
domain for the IFN-α-inducible double-stranded RNA-
dependent PKR was identified within the carboxy-ter-
minal portion of NS5A in HCV 1 isolates. The PKR 
binding domain includes the previously described IFN 
sensitivity determining region (ISDR) (Enomoto et al. 
1995, 1996). The binding of NS5A to PKR results in the 
inhibition of protein synthesis with a subsequent anti-
viral effect in vitro (Gale et al. 1998b). Clinical studies 
have addressed the question of whether the number of 
NS5A aa variations in HCV isolates from patients who 
did or did not respond to IFN-α based therapy is associ-
ated with treatment outcome. So far, the number of aa 
variations within the ISDR and within the entire NS5A 
protein from HCV genotype 1b isolates may be a pre-
dictor for SVR (Pascu et al. 2004). More recently, clini-
cal studies have proposed that the number of aa varia-
tions within variable region V3 and its flanking regions 
may be associated with treatment outcome (Castelain 
NS5A and E2 of HCV-3a in Brazilian patients • Fernanda de Mello Malta et al. 93
et al. 2002, Sarrazin et al. 2002, Puig-Basagoiti et al. 
2005). Cellular expression of the NS5A protein from 
HCV genotype 1a/b confirmed the inhibitory effects 
on IFN-α activity V3 region sequence variability and 
was shown to correlate with virologic response in HCV 
genotype 1 infected patients (Polyak et al. 1999, Fran-
cois et al. 2000, Nousbaum et al. 2000, Sarrazin et al. 
2000a, Podevin et al. 2001).
In the present paper, we investigated the aa substi-
tutions within E2 (PePHD) and NS5A from Brazilian 
patients chronically infected with HCV genotype 3a 
and their correlation with response to antiviral therapy 
(IFN-α plus RBV).
PAtiENtS, MAtERiALS ANd MEtHodS
Thirty-three patients chronically infected with HCV 
genotype 3a from the Hepatology Branch, Department 
of Gastroenterology, University of São Paulo, School 
of Medicine, São Paulo, Brazil were enrolled. Clini-
cal, biochemical and histological characteristics of the 
enrolled patients were obtained from their medical re-
cords and are summarised in Table I. Histological activ-
ity grade and fibrosis stage were evaluated according to 
the METAVIR scoring system (cirrhotic, n = 16; non-
cirrhotic, n = 17) (Bedossa & Poynard 1996).
Response to IFN-α/RBV treatment was assessed at 
the end of therapy and six months after stopping therapy. 
HCV-RNA was determined for sera using a commer-
cially available qualitative PCR assay (AMPLICOR™, 
50 IU/mL detection limit, Roche Molecular Systems, 
CA, USA). Patients who achieved HCV-RNA clearance 
for more than six months after the end of therapy were 
considered to be SVR (SVR, n = 16). Patients who be-
came HCV-RNA negative during the course of therapy 
but then relapsed and showed detectable HCV-RNA af-
ter stopping treatment were considered non-responders 
(NR) (n = 17). Informed consent to participate was ob-
tained from each patient. This study was approved by 
the local Ethical Committee.
HCV-RNA extraction - HCV-RNA was extracted 
from 140 µL of pre-treatment serum using a commer-
cially available kit (QIAamp® Viral RNA, QIAGEN, 
Inc, Hilden, Germany). Complementary DNA was 
generated using M-MLV reverse transcriptase and 
random hexamers (InvitrogenTM, Carlsbad, CA, USA). 
After incubation at 70ºC for 10 min, reverse transcrip-
tion was carried out at 37°C for 60 min, followed by 
heat inactivation at 95°C for 15 min.
Amplification of the HCV E2 and NS5A regions - 
Polymerase chain reactions (PCRs) were performed us-
ing Elongase® Enzyme Mix DNA polymerases (Invitro-
genTM, Carlsbad, CA, USA) and a set of specific primers 
for each gene (Table II).
The PCRs for amplifying the C-terminal region of 
the E2 protein (240 bp fragment) comprising the PePHD 
were performed in two rounds under equivalent condi-
tions: 30 cycles, with each cycle consisting of denatur-
ation at 94°C for 15 sec, annealing at 55°C for 30 sec, 
extension at 68°C for 40 sec, followed by a final exten-
sion at 68°C for 3 min.
The HCV NS5A gene (codons 1979-2414) was ampli-
fied by nested PCR in four overlapping parts with differ-
ent sets of primers (Table II). The first round of PCR was 
performed using the external primers (NS4B_595 and 
NS5B_159a), after an initial denaturation step of 94°C 
for 2 min, 35 cycles of 94°C for 30 sec, 48°C for 30 sec 
and 68°C for 1 min. The second round was performed 
using four sets of internal primers [F1S and F1AS (551 
bp), F2S and F2AS (545 bp), F3S and F3AS (439 bp) and 
F4S and F4AS (423 bp)] under the following conditions: 
an initial denaturation step of 94°C for 2 min, 30 cycles 
of 94°C for 15 sec, 62°C for 30 sec and 68°C for 45 sec. 
After cycling, a final extension period at 68°C for 3 min 
was added for all reactions. The amplified fragments 
were visualised by 2% agarose gel electrophoresis and 
ethidium bromide staining.
Strict procedures for nucleic acid amplification di-
agnostic techniques were followed during pre and post-
amplification to avoid false-positive results and posi-
tive and negative controls were always included in each 
set of reactions.
Sequence analysis - The PePHD region of E2 pro-
tein and the cytoplasmic retention signal (CRS), ISDR, 
PKR-binding, nuclear localisation signal (NLS) and 
V3 domains from NS5A protein were characterised 
by the direct sequencing of one pre-treatment serum 
sample from each patient. Sequencing was performed 
by the PCR direct sequencing method. The nucleotide 
sequence was determined by the dideoxy method using 
the ABI Prism BigDye terminator cycle sequencing kit 
and the sequencing gels were run on an ABI Prism 377 
DNA automated sequencer (Applied Biosystems, Foster 
City, CA, USA). Each amplicon was analysed in both the 
sense and antisense direction.
All of the sequences obtained in this study were 
aligned and the most frequent aa at each position was 
defined as the consensus sequence. The deduced aa se-
quences of the E2 (PePHD) and NS5A domains of HCV 
were compared with the consensus sequence and with the 
prototype isolate for HCV-3a (NZL-1/D17763). Multiple 
aa sequence alignment was carried out using CLUSTAL 
X (version 1.81) and MEGA (version 2.1) (http://www.
megasoftware.net/) was used to analyse aa sequences 
(Thompson et al. 1997, Kumar et al. 2001). The correla-
tion between the number of mutations and the response 
to the treatment, in each of the region, was studied tak-
ing into account the median number of mutations in each 
region. In this way the populations of each region were 
distributed into two groups (E2 aa 636-708, > or ≤ 1; 
PePHD, without mutations or ≥ 1; CRS, without or ≥ 1; 
ISDR, without or ≥ 1; PKR-binding, > or ≤ 1; NLS, with-
out or 1; extended-V3, > or ≤ 3; NS5A aa 1979-2414, > or 
≤ 13). This approach was used by Muñoz de Rueda et al. 
(2008) in a similar study involving patients infected only 
by HCV genotype 1.
Statistical analysis - Statistical analysis was per-
formed using Minitab, version 15.1.1.0 (Minitab Inc, State 
College, PA, USA). Descriptive statistics was carried out 
according to the nature of the variables and the results are 
presented in the Tables. The quantitative variables are ex-
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pressed as means and standard deviations. Comparisons 
between groups (SVR and NR) were carried out using 
χ2 or Fisher’s exact test for categorical variables and the 
Student’s t-test for quantitative variables. A p value less 
than 0.05 was considered statistically significant.
Nucleotide sequence accession numbers - Nucle-
otide sequence data reported in this paper was submit-
ted to GenBank (http://www.ncbi.nlm.nih.gov/) with the 
accession EF207987-EF208018 for the NS5A sequences 
and EF210487-EF210519 for the E2 sequences.
RESuLtS
Comparison of the total number of aa changes in 
NS5A in SVR and NR patients - The NS5A region of 
HCV genotype 3a was amplified and sequenced from 
the sera of 32 pre-treated patients; this region was not 
amplified in only one sample. As we found mutations 
related to NZL-1 that occurred repeatedly in all of our 
patients, we decided to determine a consensus sequence 
for all patients participating in this study. We obtained 
results similar to those obtained with the reference 
strand. Mutations were always defined with respect to 
the consensus sequence of all NS5A sequences investi-
gated in this study.
The aa sequences were deduced and then compared 
to the consensus sequence (Fig. 1). The total number of 
aa changes in NS5A did not differ between SVR and NR. 
Also, when the analyses were restricted to CRS, ISDR, 
TABLE I
Comparative analysis of demographic characteristics (clinical, biochemical and histological factors) between sustained  
virological response (SVR) and non-responders (NR) patients with chronic hepatitis C virus infection
Factors SVR (n = 16) NR (n = 17) p value
Age 42.31 ± 8.15a 44.71 ± 8.61 (0.419)d
Sex (M/F) 11/5 11/6 (0.805)d
ALT (mean x ULN) 2.08 ± 0.95 3.05 ± 1.72 (0.053)d
AST (mean x ULN) 1.88 ± 0.92 3.06 ± 2.54 (0.086)d
Staging of fibrosis (0-2b/3-4c) 9/7 8/9 (0.598)d
Hepatic steatosis (absent/present) 3/13 2/15 (0.576)d
a: mean ± SD; ALT: alanine aminotransferase; AST: aspartate aminotransferase; b: non-cirrhotic; c: cirrhotic; d: not significant; 
ULN: upper limit of normal.
TABLE II
Primers for amplification of the E2 and NS5A genes of hepatitis C virus (HCV) genotype 3a
Region and application Direction Primer Sequence Positiona
E2
   First PCR Sense E2_616S 5’-TGC CCC ACC GAC TGC TTC AG-3’ 2098-2117
Antisense NS2_125AS 5’-CAT ATG GTG TAC TGG TTC CAC C-3’ 2888-2909
   Second PCR and sequencing Sense E2_1Sb 5’-TTG TTC AAG GTG AGG ATG TT-3’ 2233-2252
Antisense E2_1ASb 5’-CCA ACG CCA TAA AGG TAT TG-3’ 2455-2474
NS5A
   First PCR Sense NS4B_595S 5’-GAG GGG GCN GTN CAG TGG ATG AA-3’ 6085-6106
Antisense NS5B_159AS 5’-GGT AAC CTT AYT CTG ACG-3’ 7771-7788
   Second PCR and sequencing Sense NS5A_F1S 5’TAT GTT CCC GAG AGC GAT GC-3’ 6157-6176
Antisense NS5A_F1AS 5’-CGG CAC TTG GCA CGG ACA CTT GAG-3’ 6685-6708
Sense NS5A_F2S 5’-GGT ACT TTC CCC ATC AAT GAG-3’ 6529-6549
Antisense NS5A_F2AS 5’-GCT GCC CAT CTC TTG CCG CCA-3’ 7054-7074
Sense NS5A_F3S 5’-GCA AGC TCA TCC GCC AGC CA-3’ 6952-6971
Antisense NS5A_F3AS 5’-GCT AGC GCC GCG GAC ACA TT-3’ 7372-7391
Sense NS5A_F4S 5’-TGT CCA TGG ATG CGC CTT ACC-3’ 7287-7307
Antisense NS5A_F4AS 5’-CTG AGT TGG GCT GAT GGG CAG-3’ 7690-7710
a: nucleotide positions according to HCV 3a prototype NZL-1 (accession D17763); b: Sarrazin et al. (2000b); Y = C ou T; N = A, 
T, C ou G.
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PKR-binding, NLS and the extended V3 regions, no sig-
nificant difference was observed between the number of 
aa variations in SVR patients compared to NR patients 
(Table III), although the difference in the CRS domain 
was nearly statistically significant (p = 0.072).
Comparison of the total number of aa changes in E2 
in SVR and NR patients - A partial sequence of the E2 
protein was determined from the sera of all 33 pre-treat-
ed patients. This region was found to be well conserved. 
To determine a potential relationship between initial 
genetic variability and the response to antiviral treat-
ment, the aa variations of SVR and NR patients were 
compared. The numbers of substitutions in PePHD and 
in other parts of the C-terminal region of E2 protein (aa 
636-708) were not associated with a SVR to the therapy 
(Table III). Aa substitutions in PePHD were seen in only 
seven out of 33 patients (Fig. 2).
diSCuSSioN
In the present paper, we set out to determine whether 
the numbers of mutations in the E2-PePHD and NS5A 
(CRS, ISDR, PKR-binding, NLS and extended V3) re-
gions of HCV genotype 3a were associated with the 
response to therapy. Previous studies have addressed 
the question of whether variations in the aa sequence 
of the HCV E2 protein are associated with patient re-
sponse to IFN-α therapy. Taylor et al. (1999) described 
that the PePHD within E2 protein interacts with PKR 
in vitro and plays an important role in suppressing 
PKR, suggesting a possible mechanism by which HCV 
may evade the antiviral effects of IFN. Mutations in 
this region are believed to influence the response to 
IFN therapy; however, other studies have reported con-
flicting results because this region is highly conserved 
(Berg et al. 2000, Cochrane et al. 2000, Gerotto et al. 
2000, Lo & Lin 2001, Murphy et al. 2002, Hung et al. 
2003, Saito et al. 2003). 
Our study showed that PePHD was highly conserved 
and no association was found between aa changes in 
this domain and the response to therapy. Only a few 
studies have reported a correlation between aa sub-
stitutions within PePHD and the effectiveness of IFN 
Fig. 1: sequence alignment of cytoplasmic retention signal (CRS), IFN sensitivity determining region (ISDR), protein kinase (PKR)-binding, 
nuclear localisation signal (NLS) and extended V3 domains of NS5A of hepatitis C virus (HCV)-3a obtained from the pre-treatment sera of re-
sponder (SVR) and non-responder patients (NR). The consensus sequence of HCV-3a isolates obtained in this study and the reference sequence 
NZL1 (accession D17763) are shown on the top. Numbers indicate the amino acid (aa) position in the NS5A. The number 1 corresponds to the 
first aa of NS5A protein. C: cirrhotic; NC: non-cirrhotic.
Fig. 2: sequence alignment of amino acid residues 636-708 in E2 pro-
tein of hepatitis C virus (HCV)-3a obtained from the pre-treatment sera 
of responder (SVR) and non-responder patients (NR). The PKR-eIF2a 
phosphorylation homology domain (PePHD) region corresponds to 
amino acid residues 665-676. The consensus sequence of HCV-3a iso-
lates obtained in this study and the reference sequence NZL1 (accession 
D17763) are shown on the top. Numbers indicate the amino acid position 
in the E2 protein according to NZL1. C: cirrhotic; NC: non-cirrhotic.
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TABLE III
Comparative analysis of mutations in E2 and NS5A regions between sustained virological response (SVR) and non-responders (NR) 
patients with chronic hepatitis C virus (HCV) infection. Data are expressed as numbers of patients with percentage in parenthesis
Region and mutations
Patients
p valuecAll (n = 33)a SVR (n = 16) NR (n = 17)b
E2
E2 (aa 636-708)
   ≤ 1 18 (55) 7 (44) 11 (65) ns (0.227)
   > 1 15 (45) 9 (56) 6 (35)
E2 (PePHD)
   without 26 (79) 11 (69) 15 (88) ns (0.225)
   ≥1 7 (21) 5 (31) 2 (12)
NS5A
CRS
   without 13 (41) 7 (44) 12 (75) ns (0.072)
   ≥1 19 (59) 9 (56) 4 (25)
ISDR
   without 7 (22) 11 (69) 14 (88) ns (0.394)
   ≥1 25 (78) 5 (31) 2 (12)
PKR-binding
   ≤ 1 18 (56) 10 (63) 8 (50) ns (0.476)
   > 1 14 (44) 6 (37) 8 (50)
NLS
   without 23 (72) 13 (81) 10 (63) ns (0.433)
   1 9 (28) 3 (19) 6 (37)
Extended V3
   ≤ 3 18 (56) 8 (50) 10 (63) ns (0.476)
   > 3 14 (44) 8 (50) 6 (37)
NS5A (aa 1979-2414)
   ≤ 13 17 (53) 8 (50) 9 (56) ns (0.723)
   > 13 15 (47) 8 (50) 7 (44)
comparisons between groups were made by the χ2 or Fisher exact test for the categorical variables. a: for NS5A domains n = 
32 (one sample was not amplified); aa: amino acid; b: for NS5A domains n = 16 (one sample was not amplified); c: p value 
of 0.05 was considered statistically significant; CRS: cytoplasmic retention signal; ISDR: interferon sensitivity determin-
ing region; NLS: nuclear localisation signal; ns: not significant; PePHD: PKR-eIF2a phosphorylation homology domain; 
PKR: protein kinase R.
therapy (Sarrazin et al. 2000b, Lo & Lin 2001, Saito et 
al. 2003, Ukai et al. 2006).
Different functions have been attributed to NS5A 
protein. So far, only aa variations found in the NS5A 
protein of HCV genotype 1b of some isolates found 
mainly in Japan have been correlated with a sustained 
virological response (Enomoto et al. 1996, Chayama et 
al. 2000, Pascu et al. 2004). European and American 
studies report conflicting results (Duverlie et al. 1998, 
Berg et al. 2000, Nousbaum et al. 2000, Sarrazin et al. 
2000a, Murphy et al. 2002). NS5A protein has always 
been a research focus in the field. The interplay be-
tween NS5A and the IFN system, as well as the role of 
NS5A in IFN resistance has generated intense interest 
and has been extensively studied (Tan & Katze 2001, 
Gale & Foy 2005). NS5A, in particular, may play a piv-
otal role in the interaction between HCV and cellular 
signal transduction pathways.
The first studies involving NS5A protein of HCV 
genotype 3 and resistance to IFN were based on ISDR 
and PKR-binding analysis. They showed little or no 
changes in the aas isolated from patients (SVR and NR) 
compared with the NZL-1 sequence and also found no 
association with the response to therapy (Saiz et al. 1998, 
Sarrazin et al. 2000a).
In line with other studies, ISDR and PKR-binding 
sequences generated in our study showed little variation 
from the consensus sequence and no association with 
treatment outcome was observed. These results may in-
dicate that, at least for HCV genotype 3a, these regions 
cannot be used alone as predictors of sustained virologi-
cal response to the current treatment.
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Kohashi et al. (2006) have identified several specific 
sites in the ISDR that critically affect replication, includ-
ing aa 2209, which were associated with a strong response 
to IFN in patients with genotype 1. Nevertheless, in our 
study we found that only one patient with SVR had a sub-
stitution in aa 2209 and two other patients (SVR and NR) 
showed substitutions only in aa 2216, but these findings 
were not correlated to therapeutic response.
Others domains of the NS5A protein were also analy-
sed: CRS, NLS and extended V3. We may speculate that 
if results maintain the same trend in a larger sample of 
patients, statistical analysis would show a significant cor-
relation between mutations in the CRS and virological 
response to treatment, as SVR patients showed a higher 
number of mutations in this region compared to NR. The 
N-terminal portion of the HCV NS5A protein (CRS) 
was characterised by Brass et al. (2002) as a membrane-
anchoring region which forms a highly conserved am-
phipathic α-helix that is rich in tryptophan residues in 
the hydrophobic portion. This portion is necessary and 
sufficient to mediate the association between the NS5A 
protein and the membrane of the endoplasmic reticulum 
(ER). Meanwhile, the hydrophilic portions (located in the 
cytosol) support the stability of the HCV replication com-
plex (Huang et al. 2005, Appel et al. 2006). Some authors 
have reported that the presence of mutations in certain 
codons in this region could lead to the loss of the ability of 
NS5A to interact with membranes, which could directly 
or indirectly harm viral replication, indicating that this re-
gion has an important role in the replication cycle of HCV 
(Brass et al. 2002, Macdonald & Harris 2004, Penin et al. 
2004). In this way, the variability detected in the CRS re-
gion of some responders in our study could at least partly 
account for the changes in viral replication kinetics. These 
changes could affect the process of anchoring this protein 
in the ER and might contribute to the reduced efficiency 
of viral replication, favouring the control of viremia and 
the action of IFN or RBV. Studies based on mutations in 
the CRS region are almost nonexistent and more mutation 
analyses in these regions are necessary.
In the present paper, no significant differences were 
found upon comparing sequence variations in the NLS 
and extended V3 domains between SVR and NR groups. 
However, other studies have shown a significant associa-
tion between treatment effectiveness and a high number 
of mutations within V3, with a significant difference be-
tween SVR and NR patients (Murphy et al. 2002, Sarrazin 
et al. 2002, Puig-Basagoiti et al. 2005, Goyal et al. 2007, 
Veillon et al. 2007). The total number of aa variations 
observed in NS5A of HCV genotype 3a isolates from our 
study was not associated with treatment response.
In summary, no significant association between 
sequence variations of E2/NS5A and response to IFN 
therapy was found. However, the lack of significant dif-
ferences between the groups could be due to the small 
sample size. Further studies on a larger number of pa-
tients are desirable to confirm or refute this finding. 
However, the present paper has provided information on 
HCV genotype 3a within Brazil; the 65 sequences (32 
sequences of NS5A and 33 sequences of E2) deposited in 
GenBank may contribute to evolutionary and epidemio-
logical studies of HCV. In recent years, much has been 
learned about the ability of NS5A to modulate the IFN 
response. However, more studies are needed to clarify its 
effects on other aspects of immunity. With the recent de-
velopment of an HCV infection model (such as the sub-
genomic HCV replicon cell culture system), future work 
will most certainly be aimed at investigating the role of 
NS5A in other aspects of the HCV life cycle, including 
viral entry and assembly. As new in vivo models evolve, 
the role of NS5A in viral replication in animal models 
will certainly be defined. Thus, future research should 
provide new clues as to the various functions of this tru-
ly remarkable multifunctional regulatory protein.
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